Skip to main content

In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.

Publication ,  Journal Article
St Clair, EW
Published in: Ann Intern Med
September 18, 2018

Duke Scholars

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

September 18, 2018

Volume

169

Issue

6

Start / End Page

JC33

Location

United States

Related Subject Headings

  • Rituximab
  • Recurrence
  • Humans
  • General & Internal Medicine
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
St Clair, E. W. (2018). In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months. Ann Intern Med, 169(6), JC33. https://doi.org/10.7326/ACPJC-2018-169-6-033
St Clair, E William. “In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.Ann Intern Med 169, no. 6 (September 18, 2018): JC33. https://doi.org/10.7326/ACPJC-2018-169-6-033.
St Clair, E. William. “In ANCA-associated vasculitis in remission, tailored vs fixed-schedule rituximab did not differ for relapse at 28 months.Ann Intern Med, vol. 169, no. 6, Sept. 2018, p. JC33. Pubmed, doi:10.7326/ACPJC-2018-169-6-033.

Published In

Ann Intern Med

DOI

EISSN

1539-3704

Publication Date

September 18, 2018

Volume

169

Issue

6

Start / End Page

JC33

Location

United States

Related Subject Headings

  • Rituximab
  • Recurrence
  • Humans
  • General & Internal Medicine
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • 3202 Clinical sciences
  • 11 Medical and Health Sciences